News
Arena Pharmaceuticals Presents Clinician and Patient Reported Outcomes Data from Phase 2b ADVISE Trial Evaluating Etrasimod in Adult Atopic Dermatitis During a Late-Breaking Session at American Academy of Dermatology VMX
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced additional data at a late-breaking session at the American Academy of Dermatology VMX Experience. Etrasimod, a novel investigational drug
Novocure Announces FDA IDE Approval and Steering Committee for KEYNOTE-B36 Trial Evaluating Tumor Treating Fields Together with Pembrolizumab in Non-Small Cell Lung Cancer
Novocure (NASDAQ: NVCR) today announced that the U.S. Food and Drug Administration (FDA) has approved its investigational device exemption (IDE) application to initiate the KEYNOTE-B36 trial
QIAGEN gibt gemeinsam mit DiaSorin bekannt, den neuen Test LIAISON® LymeDetect® zur Frühdiagnose der Lyme-Borreliose in Ländern einzuführen, die das CE-Zeichen akzeptieren
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) und DiaSorin (FTSE MIB: DIA) haben heute die Einführung des TestsLIAISON® LymeDetect® in Ländern bekannt gegeben, die das CE-Zeichen
QIAGEN, in partnership with DiaSorin, announces the launch of the new LIAISON® LymeDetect® Assay based on QuantiFERON technology in countries accepting CE Mark for early diagnosis of Lyme Borreliosis
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and DiaSorin (FTSE MIB: DIA) today announced the launch of the LIAISON® LymeDetect® Assay for markets accepting the CE Mark, as an aid to
QIAGEN führt artus Prep&Amp als CE gekennzeichneten SARS-CoV-2-Test mit bis zu dreifacher täglicher Durchsatzerhöhung für PCR Labore ein
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die Einführung des artus® SARS-CoV-2 Prep&Amp UM Kits bekannt, das durch eine flüssigkeitsbasierte Probenvorbereitungstechnologie den
QIAGEN Launches artus Prep&Amp as CE-Marked SARS-CoV-2 Test Offering up to Threefold Increase in Daily Lab Testing Capacity
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the artus® SARS-CoV-2 Prep&Amp UM Kit which uses a liquid based sample preparation technology to simplify and
LivaNova Receives FDA 510(k) Clearance for B-Capta, the New In-Line, Blood-Gas Monitoring System Integrated Into the S5 Heart-Lung Machine
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for B-Capta®, the new
QIAGEN N.V. to Report First Quarter 2021 Results
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced today that it plans to release its report on results for the first quarter 2021 on Monday, May 3, at approximately 22:05 Central
AMN Healthcare CSR Report Shows How AMN Fulfilled Its Social Responsibility in a Year of Unprecedented Challenges
AMN Healthcare (NYSE: AMN), the leader and innovator in healthcare workforce solutions and staffing services to healthcare facilities across the nation, released its 2020 Corporate Social
LivaNova Achieves Clinical Milestone in Heart Failure Program
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it has randomized the 300th patient in the Autonomic Regulation Therapy to Enhance Myocardial
Charles River Laboratories Schedules First-Quarter 2021 Earnings Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2021 financial results on Tuesday, May 4th, before the market opens. A conference call has been scheduled to
Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the AACR Annual Meeting 2021
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced
Novocure Announces 26 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2021 Suggesting Broad Applicability of Tumor Treating Fields
Novocure (NASDAQ: NVCR) today announced 26 presentations on Tumor Treating Fields suggesting broad applicability of Tumor Treating Fields at the American Association for Cancer Research (AACR)
Community Healthcare System Partners with Premier, Inc. to Drive Operational Innovation and High-Quality Patient Care
Community Healthcare System, recognized for high-quality care across Northwest Indiana, has partnered with Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company. Through this new
QIAGEN erweitert Test-Portfolio um Antigen-Schnelltests für den deutschen Markt
QIAGEN hat heute angekündigt, mehrere Millionen Antigen Schnelltests für Unternehmen in Deutschland ab sofort liefern zu können um die Wirtschaft bei ihrer Selbstverpflichtung zum Testen von
Chemed To Report First-Quarter 2021 Earnings April 27, Related Conference Call To Be Held On April 28
Chemed Corporation (NYSE:CHE) today announced that it will release financial results for the first quarter ended March 31, 2021, on Tuesday, April 27, 2021, following the close of trading on the
QIAGEN ergänzt COVID-19-Portfolio um neue, ultraschnelle Sequenzierungslösung für eine Genomüberwachung mit hohem Durchsatz
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die Einführung des QIAseq DIRECT SARS-CoV-2 Kit bekannt, einer Lösung zur Virusgenom-Anreicherung und Bibliotheksvorbereitung, mit
Premier, Inc. to Report Fiscal 2021 Third-Quarter Results and Host Conference Call on May 4, 2021
Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2021 third quarter on Tuesday, May 4, 2021, at approximately 6:30 a.m. ET. The company will also
QIAGEN Adds to COVID-19 Portfolio With New Ultra-Fast Sequencing Solution for High-Throughput Genomic Surveillance
QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard:QIA) today announced the launch of QIAseq DIRECT SARS-CoV-2 Kit, a viral genome enrichment and library preparation solution that significantly
Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities
Charles River Laboratories International, Inc. (NYSE: CRL) and Valence Discovery today announced the formation of a strategic partnership to provide clients access to Valence’s artificial
AMN Healthcare to Host First Quarter 2021 Earnings Conference Call on Thursday, May 6, 2021
AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations, has scheduled a conference call to discuss its first quarter 2021
Novocure to Report First Quarter 2021 Financial Results
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2021 on Thursday, April 29, 2021, before the U.S. financial markets open. Novocure’s management
Charles River Laboratories Acquires Retrogenix
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has acquired Retrogenix Limited, an early-stage contract research organization (CRO) providing specialized
Acadia Healthcare Forms Joint Venture with Geisinger to Build Two State-of-the-Art Behavioral Health Facilities in Northeastern and Central Pennsylvania
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it has formed a joint venture with Geisinger Health, one of Pennsylvania’s premier, integrated healthcare systems. The new
VFMCRP and Cara Therapeutics announce European Medicines Agency has accepted to review the Marketing Authorization Application for difelikefalin
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210329005652/en/
Vifor Fresenius Medical Care Renal Pharma (VFMCRP)